TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is PD-L1 positive per central laboratory review~* At least one measurable lesion~* Radiographic progression of NSCLC after treatment with a platinum-containing doublet for Stage IIIB/IV or recurrent disease~* Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1~* Adequate organ function~Exclusion Criteria:~* Systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks of the first dose of trial treatment~* Systemic steroid therapy within 3 days prior to the first dose of trial treatment or any other form of immunosuppressive medication~* Expected to require any other form of systemic or localized antineoplastic therapy while on trial~* History of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cancer~* Active central nervous system (CNS) metastases and/or carcinomatous meningitis~* Active autoimmune disease or documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents~* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody~* Concurrent or past history of interstitial lung disease~* Pregnant or breast-feeding, or expecting to conceive or father children within the projected duration of the study, starting with screening visit through 120 days after the last dose of pembrolizumab

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab 10 mg/kg (Type: EXPERIMENTAL): Participants receive pembrolizumab 10 mg/kg intravenously over 30 minutes on Day 1 of each 21-day cycle for up to 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria~* ≥1 year of age at the day of screening visit.~* Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening~* Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment~* Meet one or more of the following criteria at the time of randomization:~  * Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR~ * Haploidentical donor~ * Unrelated donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B, -C, or -DR~ * Use of umbilical cord blood as stem cell source~ * Ex vivo graft manipulation resulting in T cell depletion~ * Lymphocyte Count \<180/mm3 and/or cluster of differentiation 4 (CD4) Count \<50/mm3~Key Exclusion Criteria:~* History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization~* Evidence of active Grade \>2 acute GVHD~* Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections~* Known history or current (suspected) diagnosis of CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies~* Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose \>0.5 mg/kg/day) within 24 hours prior to dosing~* Relapse of primary malignancy other than minimal residual disease~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Posoleucel (ALVR105) (Type: EXPERIMENTAL): Administered as 2-4 milliliter infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female subject ≥1 month and \<17 years of age.~2. American Society of Anesthesiologists (ASA) Physical Status I, II or III.~3. Requires non-intubated, spontaneous breathing, moderate to deep sedation (NI MDS) for a magnetic resonance imaging (MRI) study with an intensivist, anesthesiologist or other proceduralist in attendance.~4. Duration of the MRI scan is expected to take at least 20 minutes but no more than 3 hours to complete~Key Exclusion Criteria:~1. Pregnant female subjects (including those with an indeterminate or positive pregnancy test); breastfeeding female subjects.~2. Weight on Day 1 before randomization is less than the 10th percentile of weight for age and sex in the US and Japan or is greater than the 95th percentile of weight for age and sex in the US or greater than the 97th percentile of weight for age and sex in Japan based on sponsor-provided growth charts.~3. Planned medical procedure during the MRI scan or post-MRI recovery period.~4. Requires endotracheal intubation or laryngeal mask airway (LMA).~5. Known allergy to eggs, egg products, soybeans or soybean products.~6. SpO2 \<93 % on room air -

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine low dose group (Type: EXPERIMENTAL): low dose of dexmedetomidine to be given
- dexmedetomidine middle dose group (Type: EXPERIMENTAL): middle dose of dexmedetomidine to be given
- dexmedetomidine high dose group (Type: EXPERIMENTAL): high dose of dexmedetomidine to be given

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CARBETOCIN VERSUS RECTAL MISOPROSTOL FOR MANAGEMENT OF THIRD STAGE OF LABOR IN WOMEN AT LOW RISK OF POSTPARTUM HEMORRHAGE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~singleton pregnancy 36-40 weeks of gestation vertex presentation. normotensive hemoglobinlevel \> 10 gm/dl~• Noncomplicated pregnancy~Exclusion Criteria:~* Women with history of Postpartum hemorrhage in previous deliveries uterine fibroids previous cesarean section medical disorders (e.g. diabetes, anemia, coagulation disorders, cardiac, hepatic and renal diseases) antepartum hemorrhage

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- CARBETOCIN (Type: ACTIVE_COMPARATOR): received 1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby.
- MISOPROSTOL (Type: ACTIVE_COMPARATOR): received 4 rectal misoprostol tablets (800 μg) after the delivery of the baby.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between 21 and 85 years old~* First heart attack within 1 to 10 days~Exclusion Criteria:~* Positive for HIV 1 and 2~* Previous heart attack~* Pacemaker or other device~* Pregnant or breastfeeding~* Allergic to cow or pig derived products~* Previous bone marrow transplant~* Involved in another clinical trial within the past 30 days~* Alcohol or recreational drug abuse within the past 6 months~* Hepatitis Positive~* Major surgical procedure or major trauma within the past 14 days~* Body weight greater than 300 pounds~* Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Provacel: Cohort 1 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Provacel: Cohort 2 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Provacel: Cohort 3 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Provacel: Cohort 4 (Type: ACTIVE_COMPARATOR): ex vivo cultured adult mesenchymal stem cells
- Placebo (Type: PLACEBO_COMPARATOR): ex vivo cultured adult mesenchymal stem cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of PTC124 in Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of DMD based on a clinical phenotype presenting by age 5, with increased serum CK and decrease of dystrophin on a muscle biopsy~* Presence of a nonsense mutation in the dystrophin gene~* Physical examination or radiographic imaging documenting the presence of EDB or TA muscles in both legs~* Ability to ambulate, or if non-ambulatory, then not requiring ventilator support~* Male sex~* Age ≥ 5 years~* Willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration and follow-up periods in subjects known to be sexually active~* Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, study restrictions, and study procedures (including muscle biopsies, myometry, and PK sampling)~* Ability to provide written informed consent (parental/guardian consent if applicable)/assent (if \<18 years of age)~Exclusion Criteria:~* Prior or ongoing medical condition (e.g., concomitant illness, psychiatric condition, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results~* Clinical symptoms and signs of congestive cardiac failure~* Positive hepatitis B surface antigen, hepatitis C antibody test, or human immunodeficiency virus (HIV) test~* Hemoglobin \<10 g/dL~* Serum albumin \<2.5 g/dL~* Abnormal GGT or total bilirubin (\>laboratory's upper limit of normal)~* Abnormal renal function (serum creatinine \>1.5 times laboratory's upper limit of normal)~* History of solid organ or hematological transplantation~* Ongoing immunosuppressive therapy (other than corticosteroids)~* Exposure to another investigational drug within 28 days prior to start of study treatment~* Ongoing participation in any other therapeutic clinical trial~* Ongoing use of thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR γ) agonists, e.g., rosiglitazone (Avandia® or equivalent) or pioglitazone (Actos® or equivalent)~* Change in systemic corticosteroid therapy (e.g., initiation of treatment; cessation of treatment; change in dose, schedule, or type of steroid) within 3 months prior to start of study treatment.~* Treatment with systemic aminoglycoside antibiotics within 4 weeks prior to start of study treatment

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese aged 6 months to 19 years~Exclusion Criteria:~* History of anaphylaxis, serious vaccine reactions, hypersensitivity to vaccine viral proteins or excipients~* Administration of adjuvanted influenza vaccine or suspected influenza disease within 3 month prior to study start~* Administration of any other vaccines within 4 weeks prior to enrollment expect for seasonal influenza vaccines within 1 week~* History of progressive or severe neurological disorders

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Dose ranging
- 2 (Type: EXPERIMENTAL): Dose ranging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin and Longevity Genes in Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-diabetes, defined as IFG (fasting glucose between 100 and 125 mg/dl) or IGT (2h post-oral glucose load (75g) between 140 and 199 mg/dl);~* Age 40-75 years;~* Both genders.~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus;~* Pregnancy, lactation;~* Acute, chronic or inflammatory diseases;~* Neoplasms;~* Immunological diseases, organ transplantation, steroid therapy;~* Uncontrolled arterial hypertension (systolic pressure \> 180 mmHg or diastolic \> 120 mmHg);~* Recent(within 3 months) surgical intervention or cardiovascular accidents;~* Known allergy to metformin.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Metformin tablets 500 mg tid for 2 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tables tid for 2 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Timing and Duration of Acute Hepatitis C Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-50 years, with or without symptoms~* Diagnosis of acute hepatitis C: elevated serum alanine aminotransferase (ALT) \> 10 times the upper limit of normal (ULN)~* Seroconversion from negative to positive anti-HCV antibody status (third-generation enzyme-linked immunosorbent assay)~* Conversion from negative to positive polymerase chain reaction (PCR) for HCV-RNA, ruling out other causes of hepatitis by history and appropriate serologic and virologic studies.~Exclusion Criteria:~* Decompensated liver disease~* Coinfection with human immunodeficiency virus (HIV) or Schistosoma mansoni~* Marked anemia (hemoglobin level ≤ 120 g/L in women and ≤ 130 g/L in men)~* Neutropenia (\< 1,500/mm3)~* Thrombocytopenia (\< 90,000/mm3)~* A creatinine concentration \> 1.5 times ULN~* Serum alpha-fetoprotein \> 25 ng/ml~* An organ transplant~* Neoplastic disease~* Severe cardiac or pulmonary disease~* Unstable thyroid dysfunction~* A psychiatric disorder~* Seizure disorder~* Severe retinopathy~* A current pregnancy or were breast feeding or unwillingness to practice contraception~* Therapy with immunomodulatory agents within the last 6 months~* Alcohol or drug dependence within 1 year of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients ≥ 40 years of age~* Patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF) according to last ATS/ERS/JRS/ALAT IPF guideline for diagnosis and management consensus~* Written informed consent prior to participation~Exclusion Criteria:~* Inability for the patient to understand or complete the written Inform Consent or patients questionnaires or to understand Spanish~* Current participation in any clinical trial~* Patients for whom further follow-up is not possible at the enrolling site

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idiopathic Pulmonary Fibrosis patients (Type: None): all IPF patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Confirmed diagnosis of invasive BCC~* Progression of disease on hedgehog inhibitor (HHI) therapy or intolerance of prior HHI therapy~* At least 1 measurable lesion~* ≥18 years of age~* Hepatic function, renal function, bone marrow function in defined lab-value-ranges~* Anticipated life expectancy \>12 weeks~* Consent to provide archived tumor biopsy material (all patients)~* Group 2: consent to undergo research biopsies~* Group 2: must not be a candidate for radiation therapy or surgery~* Comply with study procedures and site visits~* Sign Subject Information Sheet and Informed Consent Form~Key Exclusion Criteria:~* Ongoing or recent significant autoimmune disease~* Prior treatment with specific pathway-blockers (PD-1/PD-L1)~* Prior treatment with immune-modulating agents within 28 days before cemiplimab~* Untreated brain metastasis that may be considered active~* Immunosuppressive corticosteroid doses (\>10mg prednisone) within 28 days prior to treatment with cemiplimab~* Active infections requiring therapy, including HIV, hepatitis~* Pneumonitis within the last 5 years~* Cancer treatment other than radiation therapy, including investigational or standard of care, within 30 days prior to treatment with cemiplimab~* Documented allergic reactions or similar to antibody treatments~* Concurrent malignancies other than BCC, other than those with negligible risk of metastases or death~* Any acute or chronic psychiatric problems~* Having received a solid organ transplantation~* Inability to undergo contrast radiological assessments~* Breastfeeding, pregnant, women of childbearing potential not using contraception~Note: Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1- metastatic BCC (Type: EXPERIMENTAL): Administration of cemiplimab in accordance with protocol dosing regimen
- Group 2 - unresectable locally advanced BCC (Type: EXPERIMENTAL): Administration of cemiplimab in accordance with protocol dosing regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subjects with histologically confirmed malignant melanoma~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS):~  * PS 0 to 1~ * PS 2~* Previously treated unresectable stage III or stage IV melanoma as per the American Joint Committee on Cancer 2010 Guidelines regardless of BRAF mutation status~* Subjects must have experienced evaluable Response Evaluation Criteria In Solid Tumors (RECIST 1.1)-defined disease progression~* Prior treatment with chemotherapy, interferon (adjuvant setting), Interleukin (IL-2), BRAF/MEK inhibitors for subjects with known BRAF mutations, Mitogen-activated or extracellular signal- regulated protein kinase (MEK) inhibitors for Neuroblastoma Ras Viral (v-ras) oncogene homolog (NRAS) mutations, and cKIT inhibitor subjects with known cKIT mutations are allowed~* Patients with CNS metastases are eligible:~  * if CNS metastases are treated, patients are asymptomatic or neurologically returned to baseline~ * if they have previously untreated CNS metastases and are asymptomatic~ * if they have leptomeningeal metastases, are treated and asymptomatic or neurologically returned to baseline with life expectancy \> 3 months~* Patients with a known history of Grades 3-4 immune-related adverse reactions during/after anti-CTLA-4 therapy if all toxicities have resolved at least to Grade 1~Exclusion Criteria:~* Subjects with untreated, active Central Nervous System (CNS) metastases are excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab (BMS-936558) (Type: EXPERIMENTAL): Nivolumab (BMS-936558) Intravenous solution every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete